



ALYMSYS® (bevacizumab-maly) is a medicine for the treatment of: metastatic colorectal cancer; non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; epithelial ovarian, fallopian tube, or primary peritoneal cancer; persistent, recurrent, or metastatic cervical cancer.¹

Alymsys
(bevacizumab-maly)



Find Out What ALYMSYS® Can Do for You

See inside:



How
ALYMSYS®
works



Receiving
ALYMSYS®
treatment



Educational resources
for different
cancer types

IMPORTANT SAFETY INFORMATION

ALYMSYS® IMPORTANT SAFETY INFORMATION includes warnings and precautions on severe and fatal hemorrhage; arterial and venous thromboembolic events; hypertension, hypertensive crisis, and hypertensive encephalopathy; renal injury, proteinuria, and nephrotic syndrome; posterior reversible encephalopathy syndrome; embryo fetal toxicity; ovarian failure; congestive heart failure; gastrointestinal perforations and fistula; surgery and wound healing complications, and infusion related reactions.


ADVERSE REACTIONS Reported adverse drug reactions in patients include epistaxis, hemorrhage, hypertension, exfoliative dermatitis, proteinuria, back pain, headache, rhinitis, taste alteration, dry skin, and lacrimation disorder.

Please see page 7 for Important Safety Information and Alymsys.us for full Prescribing Information.



What Is ALYMSYS® (bevacizumab-maly)?

ALYMSYS® is an FDA-approved treatment for various types of cancer. Your doctor may prescribe ALYMSYS® on its own, or in combination with other medication, to treat any of the following¹:



ALYMSYS® is a certain kind of drug called a biosimilar¹

A biosimilar is a drug that was created to be highly similar to an existing drug used to treat the same disease. Biosimilars are extensively studied and tested to ensure they are just as safe and effective as the medicines they are based on, and are of equal quality. ALYMSYS®, which is manufactured and produced in Spain, is a biosimilar based on a treatment called Avastin® (bevacizumab).^{1,2}

FDA, Food and Drug Administration.

IMPORTANT SAFETY INFORMATION

Indications and Usage

ALYMSYS® (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

- Metastatic colorectal cancer, in combination with intravenous fluorouracil based chemotherapy for first or second line treatment
- Metastatic colorectal cancer, in combination with fluoropyrimidine irinotecan or fluoropyrimidine oxaliplatin based chemotherapy for second line treatment in patients who have progressed on a first line bevacizumab product containing regimen

Please see page 7 for Important Safety Information and Alymsys.us for full Prescribing Information.

How ALYMSYS® Works to Fight Your Cancer



Targeted therapy works differently than chemotherapy, which kills existing cancer cells.³

Depending on your diagnosis, your doctor may prescribe ALYMSYS® for you in combination with other medications, which could include chemotherapy¹

IMPORTANT SAFETY INFORMATION

Indications and Usage (cont'd)

ALYMSYS® (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

- First Line non squamous non small cell lung cancer, in combination with carboplatin and paclitaxel
- Recurrent glioblastoma in adults
- Metastatic renal cell carcinoma in combination with interferon alfa

Alymsys
(bevacizumab-maly)

Receiving Your ALYMSYS® (bevacizumab-maly) Treatment¹

ALYMSYS® is given as an IV infusion every 2 or 3 weeks, depending on your diagnosis¹

Metastatic colorectal cancer	Non-squamous non-small cell lung cancer	Recurrent glioblastoma	Metastatic renal cell carcinoma	Epithelial ovarian, fallopian tube, or primary peritoneal cancer	Persistent, recurrent, or metastatic cervical cancer
Every 2 or 3 weeks depending on dose level	Every 3 weeks	Every 2 weeks	Every 2 weeks	Every 2 or 3 weeks depending on dose level*	Every 3 weeks

1 Your first infusion will be administered over **90 minutes**¹

2 The second infusion will be administered over **60 minutes**¹

3+ All infusions from that point **until the end of your treatment** will be administered over **30 minutes**¹

*If prescribed 10 mg/kg of ALYMSYS® in combination with topotecan, ALYMSYS® treatment is given every two weeks, while topotecan is given every week.¹ IV, intravenous

IMPORTANT SAFETY INFORMATION

Indications and Usage (cont'd)

ALYMSYS® (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

- Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel

Limitations of Use: ALYMSYS® is not indicated for adjuvant treatment of colon cancer.

Please see page 7 for Important Safety Information and Alymsys.us for full Prescribing Information.

4

Side Effects of ALYMSYS®

It's likely that you will experience side effects from your ALYMSYS® treatment. This is normal, and most side effects will resolve over time.⁴ Your treatment team will carefully monitor how your body responds to ALYMSYS® and stay in close contact with your doctor about any adjustments that might need to be made to your dose.¹

The most common side effects of ALYMSYS® include¹:



Before receiving your ALYMSYS® treatment, tell your doctor if you¹:

- Are pregnant, plan to become pregnant, or plan to start a family in the future
- Are breastfeeding or plan to breastfeed
- Have any other health problems
- Have had major surgery within the last month, or problems with wound healing

Serious side effects can occur with ALYMSYS®. Contact your doctor right away if you experience any of the following¹:

- High fever or chills
- Persistent or severe abdominal pain
- Severe constipation
- Vomiting
- Coughing or spitting blood
- Headache, seizure, low energy, confusion, blindness, or any other changes in vision and brain function

Alymsys
(bevacizumab-maly)

5

Resources for Support

Learning more about your disease

You may find it useful to know more about your cancer. Below are some websites that could help you understand what to expect after your diagnosis.

American Cancer Society	www.cancer.org
CDC	www.cdc.gov
The ASCO Foundation	www.cancer.net
National Cancer Institute	www.cancer.gov

Please see page 7 for Important Safety Information and Alymsys.us for full Prescribing Information.

Important Safety Information

Indications and Usage

ALYMSYS® (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

- Metastatic colorectal cancer, in combination with intravenous fluorouracil based chemotherapy for first or second line treatment
- Metastatic colorectal cancer, in combination with fluoropyrimidine irinotecan or fluoropyrimidine oxaliplatin based chemotherapy for second line treatment in patients who have progressed on a first line bevacizumab product containing regimen
- First Line non squamous non small cell lung cancer, in combination with carboplatin and paclitaxel
- Recurrent glioblastoma in adults
- Metastatic renal cell carcinoma in combination with interferon alfa
- Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel

Limitations of Use: ALYMSYS® is not indicated for adjuvant treatment of colon cancer.

ALYMSYS® IMPORTANT SAFETY INFORMATION includes warnings and precautions on severe and fatal hemorrhage; arterial and venous thromboembolic events; hypertension, hypertensive crisis, and hypertensive encephalopathy; renal injury, proteinuria, and nephrotic syndrome; posterior reversible encephalopathy syndrome; embryo fetal toxicity; ovarian failure; congestive heart failure; gastrointestinal perforations and fistula; surgery and wound healing complications, and infusion related reactions.

ADVERSE REACTIONS Reported adverse drug reactions in patients include epistaxis, hemorrhage, hypertension, exfoliative dermatitis, proteinuria, back pain, headache, rhinitis, taste alteration, dry skin, and lacrimation disorder.

Alymsys
(bevacizumab-maly)

Alymsys[®]
(bevacizumab-maly)

Finding the Path Forward with ALYMSYS[®] (bevacizumab-maly)

Treating cancer is a team effort. Between your healthcare provider and your treatment team, you can start your ALYMSYS[®] treatment knowing there will always be someone there to help. If you have any questions regarding medicines prescribed, please contact your Veterans Affairs pharmacy.



An FDA-approved biosimilar
to Avastin[®] (bevacizumab)¹

Alymsys[®]
(bevacizumab-maly)

You can report any suspected adverse reactions to Amneal, at **1-877-835-5472**, or to the FDA, at **1-800-FDA-1088**, or www.fda.gov/medwatch

References: **1.** ALYMSYS. Package insert. Amneal Pharmaceuticals LLC; 2022. **2.** US Food and Drug Administration. Biosimilar basics for patients. Accessed April 1, 2023. <https://www.fda.gov/drugs/biosimilars/biosimilar-basics-patients#:~:text=> **3.** American Cancer Society. How targeted therapies are used to treat cancer. Accessed April 1, 2023. <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/what-is.html> **4.** American Cancer Society. Targeted therapy side effects. Accessed April 1, 2023. <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/side-effects.html>

amnealbiosciences.com | amneal.com

ALYMSYS[®] is a registered trademark of mAbxience Research, SL.

Avastin[®] (bevacizumab) is a registered trademark of Genentech USA, Inc.

©2025 Amneal Pharmaceuticals LLC. All rights reserved. PP-PAT-ALYMS-US-0003 11/25

